As Promised, Alnylam Forms Another Big Pharma Alliance, This Time With Takeda

The deal, which comes less than two weeks after Alnylam’s CEO told Wall Street that his company can still clinch large-scale alliances with drug makers, could be worth more than $1 billion to Alnylam, which has granted Takeda worldwide, non-exclusive access to its IP and technology to help develop drugs for cancer and metabolic diseases.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.